Mode
Text Size
Log in / Sign up
N/A N=49 Randomized Quadruple-blind Prevention

Use of NAC in Alleviation of Hangover Symptoms

Hangover Symptoms, NAC

Enrolled (actual)
49
Serious AEs
0.0%
Results posted
May 2018
Primary outcome: Primary: Hangover Symptom Scale — 10; 13; 1; 1 units on a scale — p=0.45

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
N Acetyl Cysteine (Dietary_supplement); placebo (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Primary completion
Dec 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Hangover Symptom Scale
10; 13; 1; 1; 0; 1 0.45

Summary

This will be a double-blinded study involving healthy non-alcoholic (self-reported) volunteers over the age of 21 to consume beer on hospital property in a safe environment to ensure immediate availability to medical attention and to security if needed. Volunteers will be recruited from residency programs, hospital employees, emergency medical personnel, and friends of study investigators. The volunteers will drink to a BAC of 0.1 as checked with a breathalyzer. They will wear a tag around their neck with their study number, which will be hole-punched with every beer consumed, which will be collected at the end of the night for an accurate count of beers consumed per person. They however will not be forced to drink anymore if they are uncomfortable with the amount of alcohol they are consuming and can withdraw from the study at any time. All participants will be required to be driven home by a sober driver once the participant's BAT is 0.02 or less. At the end of the night, the volunteer will be breathalyzed to determine BAC, and given 1 capsule per 3 drinks consumed of either 600 mg N-Acetyl-L-Cysteine or placebo capsules. In the morning, each participate will fill out a Hangover Symptom Score questionnaire, evaluating each hangover symptom on a 0 - 4 point Hangover Symptom Severity scale. A random number generator will be used to determine Placebo or NAC first, then the participant will be given the other treatment at their subsequent encounter. The study will be conducted over the series of many months, and data can be analyzed by self-control comparing the participant's hangover symptom severity as determined by the hangover symptom scale data when using NAC compared to placebo. The data will be analyzed using the numerical values of each category for hangover classification and compare the placebo data to the control data.

Eligibility Criteria

Inclusion Criteria

  • healthy volunteers over age 21 years

Exclusion Criteria

  • Volunteers will be excluded from the study if they suffer from any of the following conditions:
  • Alcoholism,
  • Pregnancy,
  • Reactive Airway Disease,
  • Diabetes,
  • Kidney or bladder stones,
  • Kidney disease,
  • Liver disease,
  • Stomach ulcer,
  • Organ transplant patients,
  • Dialysis patients,
  • and patients with alcohol, egg, milk or wheat allergies.

Volunteers taking the following medications will not be able to participate:

  • activated charcoal,
  • ampicillin,
  • carbamazepine,
  • cephaloridine,
  • cloxacillin,
  • methicillin,
  • nitroglycerine,
  • oxacillin,
  • penicillin G,
  • or quinacillin.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02541422). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search